ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 168 filers reported holding ESPERION THERAPEUTICS INC NE in Q3 2020. The put-call ratio across all filers is 0.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $21,280 | -10.7% | 21,714 | +26.7% | 0.00% | – |
| Q2 2023 | $23,819 | +4.5% | 17,136 | +19.5% | 0.00% | – |
| Q1 2023 | $22,797 | -90.4% | 14,338 | -62.2% | 0.00% | – |
| Q4 2022 | $236,291 | +242.5% | 37,928 | +249.9% | 0.00% | – |
| Q2 2022 | $69,000 | -89.2% | 10,840 | -52.3% | 0.00% | -100.0% |
| Q1 2021 | $637,000 | +111.6% | 22,721 | +96.5% | 0.00% | – |
| Q4 2020 | $301,000 | -9.1% | 11,560 | +30.0% | 0.00% | – |
| Q3 2020 | $331,000 | +29.8% | 8,893 | +79.1% | 0.00% | – |
| Q2 2020 | $255,000 | +7.6% | 4,965 | +24.9% | 0.00% | – |
| Q4 2019 | $237,000 | +0.9% | 3,975 | -21.4% | 0.00% | – |
| Q2 2019 | $235,000 | -20.9% | 5,060 | -24.5% | 0.00% | – |
| Q3 2018 | $297,000 | +23.2% | 6,699 | +28.8% | 0.00% | -100.0% |
| Q2 2017 | $241,000 | – | 5,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 4,468,835 | $20,735,000 | 8.65% |
| Altium Capital Management LP | 2,496,524 | $11,584,000 | 3.88% |
| Deep Track Capital, LP | 6,000,000 | $27,840,000 | 1.78% |
| Paradigm Biocapital Advisors LP | 1,157,246 | $5,370,000 | 1.42% |
| Monaco Asset Management SAM | 419,262 | $1,945,000 | 0.77% |
| Rhenman & Partners Asset Management AB | 981,582 | $4,555,000 | 0.45% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $12,589,000 | 0.39% |
| Bellevue Group AG | 4,299,164 | $19,948,000 | 0.23% |
| WASATCH ADVISORS LP | 8,147,380 | $37,804,000 | 0.19% |
| Telemetry Investments, L.L.C. | 17,500 | $81,000 | 0.13% |